Regulatory Considerations on the Development, Evaluation, and Approval of Therapies in Rheumatoid Arthritis Prevention

Clin Ther. 2019 Jul;41(7):1397-1400. doi: 10.1016/j.clinthera.2019.05.011. Epub 2019 Jun 12.

Authors

Claudia Richard¹, Joseph A Hedrick²

Affiliations

¹ Janssen Research & Development LLC, Toronto, Ontario, Canada. Electronic address: crichar2@its.jnj.com.
² Janssen Research & Development LLC, Raritan, NJ, USA.

PMID: 31202507
DOI: 10.1016/j.clinthera.2019.05.011

No abstract available

Keywords: Endpoints; Health authorities; Pre-symptomatic; Prevention; Rheumatoid arthritis.

Publication types

Letter